Coronavirus Disease (COVID-19)
References

References

References

  1. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the
  2. Treatment of Covid-19 - Final Report. N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8. PMID: 32445440; PMCID: PMC7262788.
  3. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17. PMID: 32678530; PMCID: PMC7383595.
  4. https://www.covid19treatmentguidelines.nih.gov/ 
  5. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorizationchloroquine-and 
  6. Guan, W and colleagues. Clinical Characteristics of Novel Coronavirus Disease 2019 in China. NEJM. Feb 28, 2020
  7. Zhou, F and colleagues Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, March 11, 2020
  8. Goyal, P and colleagues. Clincal Characteristics of Covid-19 in New York City. NEJM April 17, 2020.
  9. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, Soucy JR, Daneman N. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020 Dec;26(12):1622-1629. doi: 10.1016/j.cmi.2020.07.016. Epub 2020 Jul 22. PMID: 32711058.
  10. van Berkel M, Kox M, Frenzel T, Pickkers P, Schouten J; RCI-COVID-19 study group. Biomarkers for antimicrobial stewardship: a reappraisal in COVID-19 times? Crit Care. 2020 Oct 6;24(1):600. doi: 10.1186/s13054-020-03291-w. PMID: 33023606; PMCID:PMC7538269.
  11. Ji, Dong and colleagues. Prediction of Progression Risk in Patients with COVID-19 Pneumonia: the CALL Score. Clinical Infect Dis. 9 April 2020.
  12. Cao, B. and colleagues. “A Trial of Lopinavir-Ritonavir in Adult Patients Hospitalized with COVID-19.” NEJM March 18 2020
  13. Wolfel, R and colleagues. “Virological assessment of hospitalized patients with COVID-19” Nature April 1 2020
  14. He, Xi. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nature Medicine, April 15, 2020
  15. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19 
  16. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 [published online ahead of print, 2020 May 27]. N Engl J Med. 2020;NEJMoa2015301. doi:10.1056/NEJMoa201530 Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Infecious Diseases Society of America. Available at https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Accessed [12/8/20].
  17. Kalil A, Patterson T, Mehta A et al. Baricitinib plus remdesivir for the treatment of hospitalized adults with Covid-19. New Eng J Med 2020 DOI: 10.1056/NEJMoa2031994
  18. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed [12/8/20].
  19. Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, Shawa I, Adams AC, Van
  20. Naarden J, Custer KL, Shen L, Durante M, Oakley G, Schade AE, Sabo J, Patel DR, Klekotka P, Skovronsky DM; BLAZE-1 Investigators. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med. 2020 Oct 28:NEJMoa2029849. doi: 10.1056/NEJMoa2029849. Epub ahead of print. PMID: 33113295; PMCID: PMC7646625.
  21. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y, Rofail D, Im J, Perry C, Pan C, Hosain R, Mahmood A, Davis JD, Turner KC, Hooper AT, Hamilton JD, Baum A, Kyratsous CA, Kim Y, Cook A, Kampman W, Kohli A, Sachdeva Y, Graber X, Kowal B, DiCioccio T, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD; Trial Investigators. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2020 Dec 17. doi: 10.1056/NEJMoa2035002.
  22. Gottlieb RL, Nirula A, Chen P, et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2021;325(7):632–644. doi:10.1001/jama.2021.0202
  23. Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, Criner GJ, Kaplan-Lewis E, Baden R, Pandit L, Cameron ML, Garcia-Diaz J, Chávez V, Mekebeb-Reuter M, Lima de Menezes F, Shah R, González-Lara MF, Assman B, Freedman J, Mohan SV. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021 Jan 7;384(1):20-30. doi: 10.1056/NEJMoa2030340. Epub 2020 Dec 17. PMID: 33332779; PMCID: PMC7781101.
  24. Marconi, V and colleagues. Baricitinib Plus Standard of Care for Hospitalized Adults with Covid-19. https://www.medrxiv.org/content/10.1101/2021.04.30.21255934v1.full.pdf